Form 4: Sarepta Therapeutics Executive Bilal Arif Reports Stock Transactions
SEC Form 4 Filing
Bilal Arif, Chief Tech Ops Officer at Sarepta Therapeutics, reports acquisition and disposal of company stock and stock options related to vesting of restricted stock units and tax obligations.
Summary
- Bilal Arif, Chief Tech Ops Officer of Sarepta Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On March 1, 2024, Arif disposed of 251 shares at $126.19 and 114 shares at $126.19 to cover tax obligations related to vesting restricted stock units.
- He also sold 1,543 shares at $128.58 and 457 shares at $129.71 to generate cash for tax payments due to the vesting of restricted stock unit awards.
- Arif acquired 6,000 shares through restricted stock units (RSUs) and also acquired 12,500 stock options with an exercise price of $128.67.
- The RSUs vest 25% annually, and the stock options vest monthly starting March 1, 2025, and expire on March 1, 2034.
- Following these transactions, Arif beneficially owns 26,722 shares of common stock and 12,500 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and does not indicate any significant positive or negative developments for the company.
Positives
- The grant of 6,000 restricted stock units and 12,500 stock options to a key executive suggests continued alignment of interests with shareholders.
Future Outlook
The reported transactions reflect ongoing compensation and equity ownership adjustments for a key executive, with vesting schedules extending into the future.
Industry Context
Form 4 filings are routine disclosures for publicly traded companies and their insiders, providing transparency into executive compensation and stock ownership. These filings are closely watched by investors seeking insights into management's perspective on the company's prospects.
Comparison to Industry Standards
- Executive compensation packages, including stock options and restricted stock units, are common in the biotechnology industry to incentivize performance and align management interests with shareholders.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation strategies for their executives.
- The vesting schedules and exercise prices are typical for such grants, designed to reward long-term value creation.
Stakeholder Impact
- The transactions have a minor impact on shareholders, reflecting adjustments in executive equity ownership.
- Employees participating in the Employee Stock Purchase Plan are indirectly affected by the stock transactions.
Key Dates
| Date | Description |
|---|---|
| 02/28/2020 | Date of restricted stock units grant related to tax withholding obligations. |
| 02/29/2024 | Date of Employee Stock Purchase Plan purchase. |
| 03/01/2024 | Date of transactions: stock disposals for tax obligations, RSU grant, stock sales, and stock option grant. |
| 03/01/2025 | Date upon which the first 25% of the option granted vests. |
| 03/01/2034 | Expiration date of the stock options. |
| 03/05/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.